Disclosures Not funded by any pharmaceutical manufacturer or seller MICIS is a program of the Maine Medical Association Program funded entirely by Maine Department of Health amp Human Services Any opinions stated are the speakers The speaker is NOT speaking for the State of Maine or the M ID: 643842
Download Presentation The PPT/PDF document "Presenter: Peter P. Michaud, Maine Medic..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Presenter: Peter P. Michaud, Maine Medical AssociationSlide2
DisclosuresNot funded by any pharmaceutical manufacturer or sellerMICIS is a program of the Maine Medical AssociationProgram funded entirely by Maine Department of Health & Human ServicesAny opinions stated are the speaker’s. The speaker is NOT speaking for the State of Maine or the Maine DHHS.Slide3Slide4
On-site, Independent, Evidence-based Prescribing Tutorials, Known as “Academic Detailing”Slide5
“Academic Detailing”“[T]he provision of information regarding prescription drugs based on scientific and medical research, including information on therapeutic and cost-effective use of prescription drugs.”
Balanced, objective, evidence-based informationIndependent of commercial relationships
Presented by cliniciansSlide6
The Goals of Academic DetailingChange thinking about prescribing to be consistent with medical evidenceSupport patient
safetyAssist
cost-effective medication choicesImprove patient careSlide7
Information SourcesA network of Academic Detailing organizations based at Harvard Medical School and Brigham & Women’s HospitalALOSA FoundationIDIS (PA & VT Independent Drug Information Service)
NaRCAD (National Resource Center for Academic Detailing)Slide8
Program PurposeEstablished by Maine Statute 22 MRSA §2685 (2007): “[T]o enhance the health of residents of the State, to
improve the quality of decisions regarding drug prescribing, to encourage better communication between the department and health care practitioners participating in publicly funded health programs and to reduce the health complications and unnecessary costs associated with inappropriate drug prescribing.”
“[I]nclude outreach and education regarding the therapeutic and cost-effective use of prescription drugs as issued in peer-reviewed scientific, medical and academic research publications.”“To the extent possible … include information regarding clinical trials, pharmaceutical efficacy, adverse effects of drugs, evidence-based treatment options and drug marketing approaches that are intended to circumvent competition from generic and therapeutically equivalent drugs.” Slide9
Program StructureFunding:$500 per year fee on all pharmaceutical manufacturers selling to MaineCare (Medicaid) or Drugs for the Elderly programMay accept funds from foundations, AG settlements, Tobacco Manufacturers Act
Contract:
State DHHS annual contract with Maine Medical AssociationMMA established MICIS program, contracts with 2 prescribing clinicians to provide academic detailing servicesRegular reporting of data and evaluations to DHHS, by DHHS to LegislatureSlide10
ModulesType II DiabetesAtrial fibrillationAntipsychoticsChronic pain
HypertensionAntibiotics
ObesityAntiplatelet therapyCOPDOpioidsHeart Failure*NaloxoneSlide11
Typical Materials Provided in a Module“Un-ad” (summary)Evidence document
Pocket cardPatient brochures
SupplementSlide12
Examples (from ALOSA Modules)Slide13
Examples (cont’d)Antipsychotic drug risks and side effects in patients with dementiaWhile APMs are FDA-approved for the treatment of major psychiatric disorders, such as schizophrenia and bipolar disorder, they are NOT approved to treat BPSD. In this population, the risks often outweigh the benefits.In a meta-analysis of 15 randomized trials, patients given an atypical antipsychotic drug had higher rates of death than patients given placebo
7Slide14
Examples (cont’d)Slide15
MICIS Take Home PointsFree CMEDelivered on-site—office, hospital, conferenceGroups of 1 to >100Independent of commercial interestsFocused on the available data & evidence
Presented by prescribing cliniciansNO FREE LUNCH!Slide16
Peter P. Michaud, JD, RN
Associate General Counsel
Maine Medical Association
pmichaud@mainemed.com
(207) 480-4199
Questions?